Title of article :
Compromised longevity due to Mycobacterium abscessus pulmonary disease in lungs scarred by tuberculosis
Author/Authors :
Singh, Urvashi B. All India Institute of Medical Sciences - Department of Microbiology, New Delhi, India , Das, Rojaleen All India Institute of Medical Sciences - Department of Microbiology, New Delhi, India , Shrestha, Prajowl All India Institute of Medical Sciences - Department of Pulmonary Medicine and Sleep Disorders, New Delhi, India , Bala, Kiran All India Institute of Medical Sciences - Department of Microbiology, New Delhi, India , Pandey, Pooja All India Institute of Medical Sciences - Department of Microbiology, New Delhi, India , Verma, Santosh Kumar All India Institute of Medical Sciences - Department of Microbiology, New Delhi, India , Gautam, Hitender All India Institute of Medical Sciences - Department of Microbiology, New Delhi, India , Story-Roller, Elizabeth Division of Infectious Diseases - School of Medicine - Johns Hopkins University, Baltimore, Maryland, USA , Lamichhane, Gyanu Division of Infectious Diseases - School of Medicine - Johns Hopkins University, Baltimore, Maryland, USA , Guleria, Randeep All India Institute of Medical Sciences - Department of Pulmonary Medicine and Sleep Disorders, New Delhi, India
Pages :
5
From page :
1
To page :
5
Abstract :
Structural lung diseases or scarring related to prior infections such as tuberculosis (TB) are risk factors for the development of invasive nontuberculous mycobacterial (NTM) pulmonary infections, such as Mycobacterium abscessus . M. abscessus is intrinsically resistant to many antibiotics and in vitro susceptibility correlates poorly with clinical response, especially in pulmonary disease. Treatment is often difficult due to the lack of effective antibiotic regimens. We present a case of a 56-year-old male previously treated for TB, with presumed exacerbation, who was diagnosed after much delay with pulmonary M. abscessus disease and subsequently failed initial treatment with an empirical antibiotic regimen. When placed on a synergistic combination regimen that included amikacin, linezolid, clarithromycin, ethambutol and faropenem, the patient showed a favourable response and was culture-negative for over 12 months when the treatment was stopped as per American Thoracic Society (ATS) recommendations. Unfortunately, he developed recurrent symptoms and died 9 months after stopping treatment, following an acute exacerbation of fever and respiratory failure.
Keywords :
M. abscessus , faropenem , pulmonary disease , tuberculosis
Journal title :
Access Microbiology
Serial Year :
2019
Full Text URL :
Record number :
2615585
Link To Document :
بازگشت